The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 30, 2021
Filed:
Jun. 10, 2020
Applicant:
Celgene Quanticel Research, Inc., San Diego, CA (US);
Inventors:
Assignee:
CELGENE QUANTICEL RESEARCH, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/513 (2006.01); A61P 35/00 (2006.01); A61K 31/7048 (2006.01); A61K 31/357 (2006.01); A61K 31/436 (2006.01); A61K 31/551 (2006.01); A61K 31/5685 (2006.01); A61K 31/5377 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/513 (2013.01); A61K 31/357 (2013.01); A61K 31/436 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); A61K 31/5685 (2013.01); A61K 31/7048 (2013.01); A61P 35/00 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01);
Abstract
Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).